MAP2K4 is altered in 2.18% of malignant solid tumor patients with MAP2K4 Loss present in 0.52% of all malignant solid tumor patients [4].

MAP2K4 Loss is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 13 are open and 2 are closed. Of the trials that contain MAP2K4 Loss and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [5].

MAP2K4 is altered in 1.09% of non-small cell lung carcinoma patients with MAP2K4 Loss present in 0.14% of all non-small cell lung carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K4 Loss and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

MAP2K4 is altered in 1.6% of melanoma patients [4].

MAP2K4 Loss is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

MAP2K4 is altered in 1.12% of non-hodgkin lymphoma patients with MAP2K4 Loss present in 0.68% of all non-hodgkin lymphoma patients [4].

MAP2K4 Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K4 Loss and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

MAP2K4 is altered in 1.82% of ovarian carcinoma patients with MAP2K4 Loss present in 0.92% of all ovarian carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 3.46% of colorectal carcinoma patients with MAP2K4 Loss present in 0.63% of all colorectal carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.85% of glioma patients with MAP2K4 Loss present in 0.06% of all glioma patients [4].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K4 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

MAP2K4 is altered in 0.67% of low grade glioma patients [4].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.5% of thyroid gland carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K4 is altered in 5.15% of breast carcinoma patients with MAP2K4 Loss present in 1.61% of all breast carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 1.49% of esophageal carcinoma patients with MAP2K4 Loss present in 0.62% of all esophageal carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 is altered in 2.34% of pancreatic adenocarcinoma patients with MAP2K4 Loss present in 0.62% of all pancreatic adenocarcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 is altered in 2.36% of pancreatic carcinoma patients with MAP2K4 Loss present in 0.6% of all pancreatic carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 1.23% of cholangiocarcinoma patients with MAP2K4 Loss present in 0.36% of all cholangiocarcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 is altered in 3.79% of gastric carcinoma patients with MAP2K4 Loss present in 0.27% of all gastric carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 is altered in 2.76% of endometrial carcinoma patients with MAP2K4 Loss present in 0.24% of all endometrial carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.15% of myelodysplastic syndromes patients with MAP2K4 Loss present in 0.18% of all myelodysplastic syndromes patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 is altered in 1.69% of soft tissue sarcoma patients with MAP2K4 Loss present in 0.11% of all soft tissue sarcoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 1.04% of squamous cell lung carcinoma patients with MAP2K4 Loss present in 0.11% of all squamous cell lung carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.17% of acute myeloid leukemia patients with MAP2K4 Loss present in 0.1% of all acute myeloid leukemia patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 is altered in 0.82% of astrocytic tumor patients with MAP2K4 Loss present in 0.04% of all astrocytic tumor patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.93% of diffuse glioma patients with MAP2K4 Loss present in 0.04% of all diffuse glioma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 is altered in 1.82% of cutaneous melanoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.54% of hepatocellular carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 2.2% of malignant peripheral nerve sheath tumor patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.47% of multiple myeloma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K4 is altered in 0.54% of neuroblastoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.61% of pilocytic astrocytoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 1.28% of poorly differentiated thyroid gland carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K4 is altered in 0.44% of renal cell carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K4 is altered in 0.82% of thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

MAP2K4 Loss is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 Loss and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].